

CAR T-CELL MANAGEMENT FROM A NURSING PERSPECTIVE

Jennifer Peterson, MSN, RN, OCN, BMTCN

Disclosures

- I do not have anything to disclose



Nursing Education

Hematology
unit

Intensive care
unit

Evaluation and
Treatment
center

Triage RNs

Ambulatory
clinics

Nursing Education

REMS training


Assessment and identification of CRS and neurotoxicity

Hematology unit


CAR T-Cell MD on call

Required documentation and notification of provider

Nursing Education



CRS toxicities by organ system.



Identified Needs

- New therapy with a unique side effect profile
- Assessment and documentation needs
- Infusion requirements
- Patient and family/caregiver education
- Quick identification of CAR T-cell patients in the EMR
- REMS training and education to meet FACT requirements

Quick Identification of CAR T-Cell Patients

0-01 Infection: None *Do Not Order Corticoste... CVAD: 1 Admit Date: 01/14/2019 Collection: Tx Plan: IP YES... Cellular T...

3.5 kg (162 lb 0.6... **Isolation: P** **Code: FULL** Length of Stay (Days): 7 Last PSA: 1.00 mg...

5 cm (5' 8.9") FYI: Cytogenetics Culture,... Adv Dir Filed?: Received HCA: None

Research: Active

Tx Plan: IP YESCARTA CAR T-CELL CONDITIONING (CYCLOPHOSPHAMIDE / FLUDARABINE) / INFUSION - NON-HODGKINS LYMPHOMA

LDA Blood Transfusion Care Plans Details Springboard Report Prof Exchange Report Summary Chemo Check... Index

Other Education Opportunities

- Added immune effector cell therapy content to the HCT class offered 3 times/year
- Presented during the nursing track curriculum at the How the Experts Treat Hematologic Malignancy conference in 2018 and 2019
- Presented to case management staff as well as rehab staff at City of Hope

Neurotoxicity Flow Sheet

- Adapted from CARTOX 10 developed by MD Anderson
- Identified need for consistent neuro assessment and documentation
- Handwriting assessment every shift

[Accordion](#)
[Expanded](#)
[View All](#)

1m

Admission (Discharged) from 10/22/		
11/22/18	11/23/18	
1955	1540	

Cognitive Assessment

Is Patient Able To State Their Name?			
Is Patient Able To State Current Month?			
Is Patient Able To State Name of This Hospital?			
Is Patient Able To Count Backwards From 100 By 10 Accurately?			
Is Patient Able To Identify Objects Correctly?			
Comments, Cognitive			

Speech Assessment

Is Patient's Speech Clear?			
----------------------------	--	--	--

Handwriting Assessment

Handwriting Changes from Previous Assessment?			
Comments, Handwriting			

Provider Notification of Neurotoxicity

Provider Name			
Provider Role			
Notification Time			
Method of Communication			
Response			

Date / Time: 10.28.18 9:55 am

To be completed by patient:

WRITE "sweet as apple pie" on the line below

sweet as apple pie

To be completed by RN:

Normal / Abnormal (circle one)

RN Signature: _____

Date / Time: 10.28.18 9:08 pm

To be completed by patient:

WRITE "sweet as apple pie" on the line below

sweetie as apple pie

To be completed by RN:

Normal / Abnormal (circle one)

RN Signature: _____

Date / Time: 10.29.18 10:48 am

To be completed by patient:

WRITE "sweet as apple pie" on the line below

sweet as apple pie

To be completed by RN:

Normal / Abnormal (circle one)

Date / Time: 10-29-18 9m q

To be completed by patient:

WRITE "sweet as apple pie" on the line below

sweet as apple pie

To be completed by RN:

Normal / Abnormal (circle one)

RN Signature: S.

Date / Time: 10-29-18 4:10 pm

To be completed by patient:

WRITE "sweet as apple pie" on the line below

sweet as apple pie

To be completed by RN:

Normal / Abnormal (circle one)

RN Signature: S.7

Date / Time: 10/30/18

To be completed by patient:

WRITE "sweet as apple pie" on the line below

10/30/18

To be completed by RN:

Normal / Abnormal (circle one)



References

- Brudno, J. and Kochenderfer, J. (2016). Toxicities of chimeric antigen receptor T cells: recognition and management. *Blood*, 127:3321-3330.
- Neelapu, S., Tummala, S., Kebriaei, P., Wierda, W., Guiterrex, C., Locke, F., Komanduri, K., Lin, Y., Jain, N., Daver, N., Westin, J., Gulbis, A., Loghin, M., de Groot, J., Adkins, S., Davis, S., Rezvani, K., Hwu, P., and Shpall, E. (2018). Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. *Nature Reviews Clinical Oncology*, 15, 47-62.